Soma (carisoprodol) produces a stronger sedative effect than Flexeril (cyclobenzaprine), but it is not more effective at relieving muscle pain or spasms. Head-to-head comparison studies have found no difference in clinical outcomes between the two drugs, including muscle spasms, pain, tenderness, and functional status. The reason Soma feels “stronger” to many people has more to do with its addictive properties than its therapeutic ones.
Why Soma Feels Stronger
Soma’s reputation as the stronger drug comes from what happens after you swallow it. Your body breaks carisoprodol down into meprobamate, a substance with sedative and anxiety-reducing effects potent enough to be classified as a Schedule IV controlled substance on its own. This metabolite is what creates the pronounced relaxation and mild euphoria some people associate with Soma. That feeling is less about muscle relief and more about central nervous system depression.
Flexeril works differently. It acts primarily in the brainstem to reduce muscle tone and spasm signals. It causes drowsiness too, but it doesn’t produce the same kind of euphoric sedation. For most people, Flexeril feels like a strong drowsy effect without the “high” that Soma can produce.
How They Compare for Pain Relief
When researchers measure what actually matters, like reductions in muscle spasms, pain levels, tenderness, and the ability to move and function normally, the two drugs perform equally well. The American Academy of Family Physicians reviewed comparison studies and concluded that no skeletal muscle relaxant has been shown to be superior to another. Cyclobenzaprine (Flexeril) is the most extensively studied of all muscle relaxants and has demonstrated effectiveness across a range of musculoskeletal conditions.
Carisoprodol (Soma), despite feeling more intense, has not outperformed Flexeril in any of these clinical measures. The stronger subjective sensation does not translate into better therapeutic results.
Dependence and Withdrawal Risk
This is the most important practical difference between the two drugs. Soma carries a real risk of physical and psychological dependence. Animal studies have shown that tolerance to carisoprodol can develop in as few as four doses. Withdrawal from Soma after prolonged use can be severe, potentially causing seizures and, in rare cases, death.
Because of this dependence risk, the DEA placed carisoprodol into Schedule IV of the Controlled Substances Act in 2012. Every prescription is tracked, and refills are limited. Flexeril, by contrast, is not a controlled substance at the federal level. While it can cause drowsiness and shouldn’t be stopped abruptly after extended use, it does not carry the same addiction profile.
The AAFP recommends that carisoprodol be reserved as a last-line therapy specifically because of its abuse potential and lack of superiority over other options.
Typical Dosages
Soma is usually prescribed at 250 to 350 mg taken three times a day and at bedtime, with treatment limited to two to three weeks. Flexeril is typically started at 5 mg three times daily and can be increased to 10 mg three times daily based on response, with a maximum of 30 mg per day. An extended-release version of Flexeril is also available at 15 mg once daily, which can be increased to 30 mg. Like Soma, Flexeril is not recommended for use beyond two to three weeks.
Side Effects
Both drugs cause drowsiness, dizziness, and headache. Flexeril is more likely to cause dry mouth because of its chemical similarity to older antidepressants. Soma is more likely to cause a feeling of intoxication, impaired coordination, and next-day grogginess. Both can be dangerous when combined with alcohol or other sedatives, but Soma’s interaction risk is higher because its meprobamate metabolite adds an extra layer of central nervous system depression.
Flexeril should not be used by people with certain heart rhythm problems or by anyone who has recently taken certain antidepressants, as it can affect electrical activity in the heart. Soma is specifically contraindicated in people with a history of acute intermittent porphyria and should be used cautiously in anyone with a history of substance use disorders.
Which One Doctors Prefer
Flexeril is prescribed far more often than Soma for short-term muscle spasm relief. It has the largest body of clinical evidence supporting its use, it carries no controlled substance restrictions, and it works just as well in comparative trials. Soma’s controlled status means more paperwork for prescribers and pharmacies, and many clinicians avoid it entirely unless a patient has tried other muscle relaxants without relief.
If you’ve been prescribed one and are wondering whether the other would work better for your pain, the clinical evidence says they perform the same. The difference is in the side effect and safety profile, and on that front, Flexeril is the lower-risk choice.